Johnson&Johnson to reinvest $1 billion to save ill-performed Xian Janssen Pharma

   Date:2013/11/25     Source:


After core business OTC drug department being designated to Shanghai Johnson& Johnson, Xian Janssen Pharma has experience overall low sales performance since its establishment 25 years ago. Founded in 1989, Xian Janssen progressed very well in OTC medicine market with the financial and technological support from Johnson&Johnson. In the height of Xian Janssen, the annual revenue could reach RMB 5.19 billion.

After Johnson&Johnson’s strategic restructure, Xian Janssen lost its core business two months ago, and it is been considered the doom day of Xian Janssen. However, Johnson&Johnson invest around $300 million to build Xian Janssen as the Asia’s biggest vaccine manufacturing base. Then, Johnson&Johnson expects to transfer its prescription drugs section into Xian Janssen to facilitate its growth aand development.

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号